Unknown

Dataset Information

0

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.


ABSTRACT: INTRODUCTION:Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a B cell-depleting anti-CD20 antibody, remains in the SLE treatment armamentarium despite failed trials in lupus nephritis and extrarenal lupus. These biologics, which operate through complementary mechanisms, might result in an enhanced depletion of circulating and tissue-resident autoreactive B lymphocytes when administered together. Thus, belimumab and rituximab combination may be a highly effective treatment of SLE. This study aims to evaluate and compare the efficacy, safety and tolerability of subcutaneous (SC) belimumab and a single cycle of rituximab in patients with SLE with belimumab alone. METHODS AND ANALYSIS:BLISS-BELIEVE is a three-arm, randomised, double-blind, placebo-controlled, 104-week superiority study. Two hundred adults with SLE will be randomised 1:2:1 to arm A, belimumab SC 200?mg/week for 52 weeks plus placebo at weeks 4 and 6; arm B, belimumab SC 200?mg/week for 52 weeks plus rituximab 1000?mg at weeks 4 and 6; arm C, belimumab SC 200?mg/week plus standard of care for 104 weeks. The 52-week treatment period (arms A and B) is followed by a 52-week observational phase. The primary efficacy endpoint is the proportion of patients with disease control (SLE Disease Activity Index (SLEDAI)-2K?2, without immunosuppressants and with a prednisone-equivalent dose of ?5?mg/day) at week 52. Major secondary efficacy endpoints are the proportion of patients in clinical remission (defined as SLEDAI-2K=0, without immunosuppressants and corticosteroids) at week 64, and the proportion of patients with disease control at week 104. Safety endpoints include the incidence of adverse events (AEs), serious AEs and AEs of special interest. ETHICS AND DISSEMINATION:Within 6 months of the study's primary manuscript publication, anonymised individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com. TRIAL REGISTRATION NUMBER:NCT03312907; Pre-results.

SUBMITTER: Teng YKO 

PROVIDER: S-EPMC6475247 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.

Teng Y K Onno YKO   Bruce Ian N IN   Diamond Betty B   Furie Richard A RA   van Vollenhoven Ronald F RF   Gordon David D   Groark James J   Henderson Robert B RB   Oldham Mary M   Tak Paul P PP  

BMJ open 20190320 3


<h4>Introduction</h4>Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a B cell-depleting anti-CD20 antibody, remains in the SLE treatment armamentarium despite failed trials in lupus nephritis and extrarenal lupus. These biologics, which operate through complementary mechanisms, might result in an enhanced depletion of circulating and tissue-resident autoreactive B lymphocytes when a  ...[more]

Similar Datasets

| S-EPMC5349337 | biostudies-literature
| S-EPMC5434872 | biostudies-literature
| S-EPMC7516125 | biostudies-literature
| S-EPMC5054300 | biostudies-literature
| S-EPMC7338653 | biostudies-literature
| S-EPMC8848800 | biostudies-literature
| S-EPMC4612697 | biostudies-literature
| S-EPMC5973992 | biostudies-literature
| S-EPMC6099508 | biostudies-literature
| S-EPMC5695978 | biostudies-literature